Literature DB >> 16703499

[Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].

M P Lichy1, P Bachert, F Hamprecht, M-A Weber, J Debus, D Schulz-Ertner, H-P Schlemmer, H-U Kauczor.   

Abstract

PURPOSE: To determine the relative signal intensity ratios of choline (Cho), phosphocreatine (CR) and N-acetyl-aspartate (NAA) in MR spectroscopic imaging (proton-MRSI) for differentiating progressive tumors (PT) from non-progressive tumors (nPT) in follow-up and treatment planning of gliomas. Threshold values to indicate the probability of a progressive tumor were also calculated.
MATERIAL AND METHODS: Thirty-four patients with histologically proven gliomas showing a suspicious brain lesion in MRI after stereotactic radiotherapy were evaluated on a 1.5 Tesla unit (Magnetom Vision, Siemens, Erlangen, Germany) using 2D proton MRSI (repetition time/echo time = 1500/135 msec, PRESS; voxel size 9 x 9 x 15 mm (3)). A total of 274 spectra were analyzed (92 voxel were localized within the suspicious brain lesion). Relative signal intensities Cho, Cr and NAA were measured and their ability to discern between PT and nPT was assessed using the linear discrimination method, logistic regression, and the cross-validation method. PT and nPT were differentiated between on the basis of clinical course and follow-up by MRI, CT and positron emission tomography.
RESULTS: The Cho parameter and the relative signal intensity ratios of Cr and NAA were most effective in differentiating between PT and nPT. The logistic regression method using the parameter ln(Cho/Cr) and ln(Cho/NAA) had the best predictive results in cross-validation. A sensitivity of 93.8 % and specificity of 85.7 % were achieved in the differentiation of PT from nPT by proton-MRSI.
CONCLUSION: (1)H-MRSI has a high sensitivity and specificity for differentiating between therapy-related effects and the relapse of irradiated gliomas. This method allows for assessment of the probability of radiotherapy response or failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16703499     DOI: 10.1055/s-2006-926744

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  7 in total

1.  Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.

Authors:  Sarah J Nelson; Achuta K Kadambi; Ilwoo Park; Yan Li; Jason Crane; Marram Olson; Annette Molinaro; Ritu Roy; Nicholas Butowski; Soonmee Cha; Susan Chang
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

2.  Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy.

Authors:  Susanne Bonekamp; Jialin Shen; Nouha Salibi; Hong C Lai; Jeff Geschwind; Ihab R Kamel
Journal:  J Comput Assist Tomogr       Date:  2011 Mar-Apr       Impact factor: 1.826

3.  Anteroposterior hippocampal metabolic heterogeneity: three-dimensional multivoxel proton 1H MR spectroscopic imaging--initial findings.

Authors:  Kevin G King; Lidia Glodzik; Songtao Liu; James S Babb; Mony J de Leon; Oded Gonen
Journal:  Radiology       Date:  2008-08-11       Impact factor: 11.105

4.  Role of advanced MR imaging modalities in diagnosing cerebral gliomas.

Authors:  T Scarabino; T Popolizio; F Trojsi; G Giannatempo; S Pollice; N Maggialetti; A Carriero; A Di Costanzo; G Tedeschi; U Salvolini
Journal:  Radiol Med       Date:  2008-12-11       Impact factor: 3.469

5.  NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Authors:  Alexander M Spence; Mark Muzi; Jeanne M Link; Finbarr O'Sullivan; Janet F Eary; John M Hoffman; Lalitha K Shankar; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

Review 6.  Targeted molecular imaging in oncology: focus on radiation therapy.

Authors:  Sridhar Nimmagadda; Eric C Ford; John W Wong; Martin G Pomper
Journal:  Semin Radiat Oncol       Date:  2008-04       Impact factor: 5.934

7.  Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.

Authors:  Sarah J Nelson; Yan Li; Janine M Lupo; Marram Olson; Jason C Crane; Annette Molinaro; Ritu Roy; Jennifer Clarke; Nicholas Butowski; Michael Prados; Soonmee Cha; Susan M Chang
Journal:  J Neurooncol       Date:  2016-08-17       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.